FDA Tightens SaMD Rules for Edge AI Validation: learn how the 2026 update affects 510(k), De Novo, latency thresholds, offline accuracy, and compliance costs for AI diagnostic software.

FDA Tightens SaMD Path for AI Diagnostics: learn how the new FDA SaMD guidance adds 6 months of real-world data to 510(k) and De Novo filings, reshaping U.S. market entry, timelines, and validation costs.

FDA Tightens SaMD Path for AI Diagnostic Software: learn how the new FDA SaMD real-world data validation rule may delay U.S. filings, reshape clinical partnerships, and impact Chinese exporters.

Digital pathology software evaluation starts with workflow, accuracy, and integration. Learn how to compare platforms, reduce risk, and choose a scalable fit for clinical use.